Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(NY:
ANRO
)
4.310
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4
Open
4.310
Bid (Size)
4.020 (2)
Ask (Size)
4.710 (1)
Prev. Close
4.310
Today's Range
4.310 - 4.310
52wk Range
3.610 - 24.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
November 04, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Performance
YTD
-79.18%
-79.18%
1 Month
-1.37%
-1.37%
3 Month
-62.94%
-62.94%
6 Month
-64.90%
-64.90%
1 Year
-79.18%
-79.18%
More News
Read More
Alto Neuroscience to Participate in Upcoming Investor Conferences
November 04, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
October 27, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Nasdaq Down 2%; US Crude Stocks Increase
October 23, 2024
Via
Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
October 23, 2024
Via
Benzinga
Gold Moves Lower; AT&T Earnings Top Views
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 23, 2024
Via
Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
October 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 23, 2024
Via
Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
October 23, 2024
Via
Benzinga
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
October 22, 2024
From
The Schall Law Firm
Via
Business Wire
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
October 22, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
September 04, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
September 03, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
July 25, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
July 16, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
June 20, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
June 18, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
June 10, 2024
Via
InvestorPlace
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
May 21, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
